US-based research and development biotechnology firm Boston Strategics has entered into a new drug development partnership with Fujifilm Pharmaceuticals USA (FPHU), a global pharmaceutical development center of Japan's Fujifilm Corporation.
The deal is the first of its kind between a Japanese pharmaceutical firm and a pharmaceutical research and development provider, creating a new and comprehensive approach to global pharmaceutical development.
As part of the deal, Boston Strategics will be the primary provider for FPHU global drug development services and resources for FPHU Oncology programs.
The agreement will build on Boston Strategic strengths covering the spectrum from preclinical and early clinical development through Phase I and II human proof-of-concept (POC).
FPHU will expand its global reach in oncology drug development by using Boston Strategics' internal oncology development expertise and ability to identify and collaborate with the best resources worldwide.
The deal will see Boston Strategics optimize and execute the global strategy of FPHU Oncology drug development programs.
In this capacity, Boston will use its 'True Open Innovation' network to provide better outcomes, using highly efficient execution strategies and proven partners, such as the University of Texas MD Anderson Cancer Center, Houston TX (MD Anderson).
Boston Strategics CEO Keizo Koya said True Open Innovation overcomes any limitations by reducing the need for large infrastructure, and draws on critical drug development expertise based on the unique needs of a particular program.
"Our strong business relationships with our global resource networks are poised to assist pharmaceutical/biotech companies with strategy and launch of quality global drug development programs, and rapidly execute them to the next decision step/value inflection point," Koya said.
"We are deeply committed to giving a new pharmaceutical R&D platform for FPHU, which look for an innovative and efficient way of globally developing their unique oncology pipelines.
"Entering into a special alliance of Boston Strategics this year with MD Anderson, a world leader in cancer treatment and oncology research, Boston Strategics will use this opportunity to provide global clinical development supports for FPHU."